American Diabetes Association

June 10, 2022

In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

June 10, 2022

In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Jasmine Gonzalvo, PharmD, joins hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents as well as newer diabetes technologies.

June 08, 2022

In our second special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, hosts Drs. Diana Isaacs and Natalie Bellini are joined by Gary Scheiner, MS, CDE. Clinical director of Integrated Diabetes Services, author of multiple books, including Think Like a Pancreas: A Practical Guide to Managing Diabetes with Insulin, and former Diabetes Educator of the Year, Scheiner joins Diabetes Dialogue to provide a deep dive into the largest diabetes meeting of the year from the view of a diabetes care and education specialist.

June 07, 2022

Eli Lilly and Company announced tirzepatide (Mounjaro) is now available in US pharmacies. We sat down with SURPASS-2 principal investigator Juan Frias, MD, at ADA 2022 and got his perspective on the potential of tirzepatide and what hesitancies clinicians may have related to the prescription of the dual GIP/GLP-1 receptor agonist.

June 07, 2022

In the first of 4 special edition ADA 2022 episodes, hosts Drs. Diana Isaacs and Natalie Bellini take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics's Insulin-Only Bionic Pancreas.

June 06, 2022

In an interview from ADA 2022, Alaina Vidmar, MD, discusses a study she led examining trends in diagnosis of type 2 diabetes among youth in the US using a database with information on 86 million patients.

June 06, 2022

Katherine Sauder, PhD, discusses a study she presented at ADA 2022 examining trends in age at diagnosis among younger patients with type 2 diabetes in the US from the landmark SEARCH study.

June 06, 2022

After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.

June 06, 2022

Although typically associated with an increased risk of type 2 diabetes, new research from Israel presented at ADA 2022 suggests increased BMI in adolescence was associated with an increased risk of new-onset type 1 diabetes in young adulthood.

June 05, 2022

A 5-year, real-world study comparing the safety and efficacy of empagliflozin against other glucose-lowering agents, EMPRISE suggests empagliflozin was associated with relative risk reductions for heart failure hospitalization greater than 50% compared with DPP-4 inhibitors and greater than 30% compared with GLP-1 receptor agonists.